ArticleFrontiers in microbiology2025
Decoding electroacupuncture's efficacy: a comparative study on gut microbiota and metabolic profiles in C57 and 3xTg-AD mice.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the impact of electroacupuncture (EA) on blood glucose, lipid profiles, and gut microbiota in WT (C57BL/6J) and 3xTg-AD mice with type 2 diabetes mellitus (T2DM) by examining fecal microbiota. Methods: C57BL/6J and 3xTg-AD mice were randomly divided into six groups ( Results: EA treatment significantly reduced body weight gain in C57 T2DM mice, but not in 3xTg-AD T2DM mice. It decreased the area under the curve (AUC) of the glucose tolerance test (GTT) after 16 weeks and improved lipid profiles by reducing total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), while increasing high-density lipoprotein cholesterol (HDL-C) in both mouse models. Overall, EA demonstrated a more pronounced therapeutic effect in C57 mice compared to 3xTg-AD mice. In both types of mice, the EA group had a higher ASV abundance compared to the HFD group. EA improved α-diversity and β-diversity, and the therapeutic efficacy were impaired in 3xTg-AD mice. Microbial diversity, richness, and composition varied between 3xTg-AD and C57 mice. In 3xTg-AD mice, there was an increase in the relative abundance of Conclusion: EA significantly enhanced glucose metabolism and lipidemia in HFD C57 mice, but its therapeutic impact was reduced in 3xTg-AD mice. The variation in gut microbiota regulation in 3xTg-AD mice could account for the response to EA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.